
Vulvovaginal Candidiasis - Pipeline Insight, 2025
Description
DelveInsight’s, “Vulvovaginal Candidiasis - Pipeline Insight, 2025,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Vulvovaginal Candidiasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Vulvovaginal Candidiasis: Overview
Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on skin without causing any problems. Sometimes Candida can multiply and cause an infection if the environment inside the vagina changes in a way that encourages its growth. Candidiasis in the vagina is commonly called a “vaginal yeast infection.” Other names for this infection are “vaginal candidiasis,” “vulvovaginal candidiasis,” or “candidal vaginitis.” The symptoms of vaginal candidiasis include: Vaginal itching or soreness, pain during sexual intercourse, pain or discomfort when urinating, abnormal vaginal discharge. Although most vaginal candidiasis is mild, some women can develop severe infections involving redness, swelling, and cracks in the wall of the vagina. Vaginal candidiasis is common, though more research is needed to understand how many women are affected. Women who are more likely to get vaginal candidiasis include those who: Are pregnant, use hormonal contraceptives (for example, birth control pills), have diabetes, have a weakened immune system (for example, due to HIV infection or medicines that weaken the immune system, such as steroids and chemotherapy). Healthcare providers usually diagnose vaginal candidiasis by taking a small sample of vaginal discharge to be examined under a microscope in the medical office or sent to a laboratory for a fungal culture. However, a positive fungal culture does not always mean that Candida is causing symptoms because some women can have Candida in the vagina without having any symptoms. Vaginal candidiasis is usually treated with antifungal medicine. For most infections, the treatment is an antifungal medicine applied inside the vagina or a single dose of fluconazole taken by mouth. Other treatments may be needed for infections that are more severe, that don’t get better, or that keep coming back after getting better.
""Vulvovaginal Candidiasis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vulvovaginal Candidiasis pipeline landscape is provided which includes the disease overview and Vulvovaginal Candidiasis treatment guidelines. The assessment part of the report embraces, in depth Vulvovaginal Candidiasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vulvovaginal Candidiasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Vulvovaginal Candidiasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vulvovaginal Candidiasis Emerging Drugs
Further product details are provided in the report……..
Vulvovaginal Candidiasis: Therapeutic Assessment
This segment of the report provides insights about the different Vulvovaginal Candidiasis drugs segregated based on following parameters that define the scope of the report, such as:
Vulvovaginal Candidiasis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vulvovaginal Candidiasis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vulvovaginal Candidiasis drugs.
Vulvovaginal Candidiasis Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Vulvovaginal Candidiasis: Overview
Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on skin without causing any problems. Sometimes Candida can multiply and cause an infection if the environment inside the vagina changes in a way that encourages its growth. Candidiasis in the vagina is commonly called a “vaginal yeast infection.” Other names for this infection are “vaginal candidiasis,” “vulvovaginal candidiasis,” or “candidal vaginitis.” The symptoms of vaginal candidiasis include: Vaginal itching or soreness, pain during sexual intercourse, pain or discomfort when urinating, abnormal vaginal discharge. Although most vaginal candidiasis is mild, some women can develop severe infections involving redness, swelling, and cracks in the wall of the vagina. Vaginal candidiasis is common, though more research is needed to understand how many women are affected. Women who are more likely to get vaginal candidiasis include those who: Are pregnant, use hormonal contraceptives (for example, birth control pills), have diabetes, have a weakened immune system (for example, due to HIV infection or medicines that weaken the immune system, such as steroids and chemotherapy). Healthcare providers usually diagnose vaginal candidiasis by taking a small sample of vaginal discharge to be examined under a microscope in the medical office or sent to a laboratory for a fungal culture. However, a positive fungal culture does not always mean that Candida is causing symptoms because some women can have Candida in the vagina without having any symptoms. Vaginal candidiasis is usually treated with antifungal medicine. For most infections, the treatment is an antifungal medicine applied inside the vagina or a single dose of fluconazole taken by mouth. Other treatments may be needed for infections that are more severe, that don’t get better, or that keep coming back after getting better.
""Vulvovaginal Candidiasis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vulvovaginal Candidiasis pipeline landscape is provided which includes the disease overview and Vulvovaginal Candidiasis treatment guidelines. The assessment part of the report embraces, in depth Vulvovaginal Candidiasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vulvovaginal Candidiasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Vulvovaginal Candidiasis R&D. The therapies under development are focused on novel approaches to treat/improve Vulvovaginal Candidiasis.
This segment of the Vulvovaginal Candidiasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vulvovaginal Candidiasis Emerging Drugs
- Oteseconazole : Mycovia Pharmaceuticals
- MAT2203: Matinas BioPharma
- Benzydamine/econazole : Angelini Pharmaceuticals
- Miconazole/Domiphen Bromide: Hyloris Pharmaceuticals
Further product details are provided in the report……..
Vulvovaginal Candidiasis: Therapeutic Assessment
This segment of the report provides insights about the different Vulvovaginal Candidiasis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Vulvovaginal Candidiasis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Vulvovaginal Candidiasis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vulvovaginal Candidiasis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vulvovaginal Candidiasis drugs.
Vulvovaginal Candidiasis Report Insights
- Vulvovaginal Candidiasis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Vulvovaginal Candidiasis drugs?
- How many Vulvovaginal Candidiasis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vulvovaginal Candidiasis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vulvovaginal Candidiasis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Vulvovaginal Candidiasis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Mycovia Pharmaceuticals
- Matinas BioPharma
- NovaDigm Therapeutics
- Toltec Pharmaceuticals
- LTN Pharm
- ProFem
- Ferrer
- Mariposa Health
- Oteseconazole
- MAT2203
- NDV 3
- Benzydamine/econazole
- Miconazole/Domiphen Bromide
- TOL 463
Table of Contents
40 Pages
- Introduction
- Executive Summary
- Vulvovaginal Candidiasis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Vulvovaginal Candidiasis– DelveInsight’s Analytical Perspective
- Late Stage Products (Pre Registration)
- Comparative Analysis
- Oteseconazole : Mycovia Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- End Stage Products (Phase III)
- Comparative Analysis
- Benzydamine/econazole : Angelini Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- MAT2203: Matinas BioPharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name:Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Vulvovaginal Candidiasis Key Companies
- Vulvovaginal Candidiasis Key Products
- Vulvovaginal Candidiasis- Unmet Needs
- Vulvovaginal Candidiasis- Market Drivers and Barriers
- Vulvovaginal Candidiasis- Future Perspectives and Conclusion
- Vulvovaginal Candidiasis Analyst Views
- Vulvovaginal Candidiasis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.